Dspe-mpeg(550) | 147867-65-0

• 物质功能分类: 化学试剂 - 有机试剂 - 多胺
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: Dspe-mpeg(550)
• 英文别名: [3-[hydroxy-[2-(2-methoxyethoxycarbonylamino)ethoxy]phosphoryl]oxy-2-octadecanoyloxypropyl] octadecanoate
• CAS: 147867-65-0
• 化学式: C₄₅H₈₈NO₁₁P
• 分子量: 850.2
• InChiKey: ULSDQCPIMGVPAF-UHFFFAOYSA-N

物化性质

• 熔点：
  53-54°C
• 溶解度：
  可溶于氯仿（少量）、甲醇（少量）

计算性质

• 辛醇/水分配系数(LogP)：
  15.2
• 重原子数：
  58
• 可旋转键数：
  48
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  156
• 氢给体数：
  2
• 氢受体数：
  11

安全信息

• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

制备方法与用途

用途

甲氧基聚乙二醇-二脂肪酰磷脂酰乙醇胺是制备脂质体的重要辅料之一，它一端是甲氧基聚乙二醇(mPEG)具有亲水性，一端是脂肪酸甘油酯具有亲酯性。

用途

利用MPEG-2000-DSPE研究肺特异性脂质体抗结核药物的稳定性、生物分布和毒性。

用途

二硬脂酰基磷脂酰乙醇胺-聚乙二醇2000用于研究肺特异性脂质体抗结核药物的稳定性，生物分布和毒性。

文献信息

• NANOEMULSIONS AND USE THEREOF AS CONTRAST AGENTS
  申请人：GUERBET

  公开号：US20140234223A1

  公开（公告）日：2014-08-21

  The invention relates to an oil-in-water nanoemulsion for MRI, including: an aqueous phase, a fluorinated phase including at least one fluorinated oil, a surfactant at the interface between the aqueous and fluorinated phases, the surfactant comprising: at least one amphiphilic targeting ligand, at least one amphiphilic lipid, and at least one diblock or triblock fluorophilic compound, as well as to the use thereof as a contrast agent.

  这项发明涉及一种用于磁共振成像的油包水纳米乳液，包括： 水相， 含有至少一种氟化油的氟化相， 位于水相和氟化相之间的表面活性剂，所述表面活性剂包括： 至少一种两性靶向配体， 至少一种两性脂质，以及 至少一种二嵌段或三嵌段亲氟化合物， 以及将其用作对比剂的用途。
• Target recognition motifs and uses thereof
  申请人：The Broad Institute, Inc.

  公开号：US10968257B2

  公开（公告）日：2021-04-06

  The disclosure provides novel programmable targeting sequences and applications thereof. The targeting sequences can be engineered for binding to proteins, polypeptides, and other macromolecules.

  本公开提供了新型可编程靶向序列及其应用。这些靶向序列可被设计用于与蛋白质、多肽和其他大分子结合。
• Combined Use of Bendamustine, Doxorubicin and Bortezomib for the Treatment of Multiple Myeloma
  申请人：Farag Sherif S.

  公开号：US20110217258A1

  公开（公告）日：2011-09-08

  Methods for treating multiple myeloma by administering a combination of a proteasome inhibitor, bendamustine and doxorubicin are described.
• MEANS FOR LUNG SPECIFIC DELIVERY
  申请人：SILENCE THERAPEUTICS GMBH

  公开号：US20160303047A1

  公开（公告）日：2016-10-20

  The present invention is related to composition comprising a lipid composition, wherein the lipid composition consists of a cationic lipid of formula (I) wherein n is any one of 1, 2, 3, and 4, wherein m is any one of 1, 2 and 3, Y′ is an anion, wherein each of R1 and R2 is individually and independently selected from the group consisting of linear C12-C18 alkyl and linear C12-C18 alkenyl; a sterol compound, wherein the sterol compound is selected from the group consisting of cholesterol and stigmasterol; and a PEGylated lipid, wherein the PEGylated lipid comprises a PEG moiety and wherein the PEGylated lipid is selected from the group consisting of a PEGylated phosphoethanolamine of formula (II) wherein each of R3 and R4 is individually and independently linear C13-C17 alkyl, and p is any integer from 15 to 130; a PEGylated ceramide of formula (III) wherein R5 is linear C7-C15 alkyl, and q is any integer from 15 to 130; and a PEGylated diacylglycerol of formula (IV) wherein each of R6 and R7 is individually and independently linear C11-C17 alkyl, and r is any integer from 15 to 130.
• TARGET RECOGNITION MOTIFS AND USES THEREOF
  申请人：The Broad Institute, Inc.

  公开号：US20190300581A1

  公开（公告）日：2019-10-03

  The disclosure provides novel programmable targeting sequences and applications thereof. The targeting sequences can be engineered for binding to proteins, polypeptides, and other macromolecules.